KSQ Therapeutics has dosed the first patient in a Phase 1/2 trial evaluating KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte therapy, for advanced solid tumors.
KSQ Therapeutics has launched a Phase 1/2 clinical trial (NCT06598371) to evaluate KSQ-004EX in patients with advanced solid tumors, including melanoma and NSCLC.
Intellia Therapeutics has initiated a pivotal Phase 3 trial (HAELO) of NTLA-2002 for hereditary angioedema, evaluating its ability to reduce HAE attacks through plasma kallikrein activity reduction.